(2025). BIKSWITCH Study: Effectiveness and Safety of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Therapies Not Based on Integrase Inhibitors in Virologically Suppressed HIV-Infected Patients. AIDS Research and Treatment.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"BIKSWITCH Study: Effectiveness and Safety of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Therapies Not Based on Integrase Inhibitors in Virologically Suppressed HIV-Infected Patients."
AIDS Research and Treatment 2025.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"BIKSWITCH Study: Effectiveness and Safety of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Therapies Not Based on Integrase Inhibitors in Virologically Suppressed HIV-Infected Patients."
AIDS Research and Treatment, 2025.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.